Abstract
Combination therapy with anti-muscarinics (AMs) and β3 agonists (β3As) has recently been proposed as a possible treatment for the management of patients with Overactive Bladder (OAB). Evidence acquisition: A National Center for Biotechnology Information PubMed search for relevant articles published between 2007 and 2014 was performed by combining the following Patient population, Intervention, Comparison, Outcome (PICO) terms: overactive bladder, antimuscarinics, β3 agonists, combination therapy, efficacy, tolerability and outcomes. Additional references were obtained from the reference list of full-text manuscripts. Abstracts presented at the annual congresses of the European Association of Urology, American Urology Association and the International Continence Society were included. Evidence Synthesis: The combination therapy, in the management of OAB symptoms, has recently been investigated in animal models and in a phase II randomized clinical trial. Compared with AMs monotherapy, combination treatment improved mean voided volume per micturition, micturition frequency and reduced urgency episodes. No dose related trends in adverse events (AEs) were observed between combination group and monotherapy group. Incidence of constipation was slightly increased in combination therapy group. Conclusions: Combination therapy seems to be an effective and safe treatment in the management of OAB. However, further cost-effectiveness studies are needed to evaluate the definitive role of this approach for the management of patients with OAB.
Keywords: Antimuscarinics, β3 agonists, combination, efficacy, overactive bladder, safety.
Current Drug Targets
Title:The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB
Volume: 16 Issue: 11
Author(s): Cosimo De Nunzio, Fabrizio Presicce, Luisella Pirozzi, Pietro Castellan, Luigi Schips, Luca Cindolo, Riccardo Lombardo and Andrea Tubaro
Affiliation:
Keywords: Antimuscarinics, β3 agonists, combination, efficacy, overactive bladder, safety.
Abstract: Combination therapy with anti-muscarinics (AMs) and β3 agonists (β3As) has recently been proposed as a possible treatment for the management of patients with Overactive Bladder (OAB). Evidence acquisition: A National Center for Biotechnology Information PubMed search for relevant articles published between 2007 and 2014 was performed by combining the following Patient population, Intervention, Comparison, Outcome (PICO) terms: overactive bladder, antimuscarinics, β3 agonists, combination therapy, efficacy, tolerability and outcomes. Additional references were obtained from the reference list of full-text manuscripts. Abstracts presented at the annual congresses of the European Association of Urology, American Urology Association and the International Continence Society were included. Evidence Synthesis: The combination therapy, in the management of OAB symptoms, has recently been investigated in animal models and in a phase II randomized clinical trial. Compared with AMs monotherapy, combination treatment improved mean voided volume per micturition, micturition frequency and reduced urgency episodes. No dose related trends in adverse events (AEs) were observed between combination group and monotherapy group. Incidence of constipation was slightly increased in combination therapy group. Conclusions: Combination therapy seems to be an effective and safe treatment in the management of OAB. However, further cost-effectiveness studies are needed to evaluate the definitive role of this approach for the management of patients with OAB.
Export Options
About this article
Cite this article as:
De Nunzio Cosimo, Presicce Fabrizio, Pirozzi Luisella, Castellan Pietro, Schips Luigi, Cindolo Luca, Lombardo Riccardo and Tubaro Andrea, The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB, Current Drug Targets 2015; 16 (11) . https://dx.doi.org/10.2174/1389450116666150806124345
DOI https://dx.doi.org/10.2174/1389450116666150806124345 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Vitamin D and Vitamin D Receptor: New Insights in the Treatment of Hypertension
Current Protein & Peptide Science Thoughtful Insights into the Therapeutic Armamentarium of Chalcones: 10 Years of Glorious Journey
Current Bioactive Compounds Prevention of Bronchopulmonary Dysplasia
Current Pediatric Reviews Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science The Role of Bone Morphogenetic Protein 4 in Lung Diseases
Current Molecular Medicine Beneficial Effects of N-acetylcysteine and N-mercaptopropionylglycine on Ischemia Reperfusion Injury in the Heart
Current Medicinal Chemistry Biomedical Advances for Spaceflight Improve Healthcare on Earth
Current Biotechnology Clinical Values of Nitric Oxide Parameters from the Respiratory System
Current Medicinal Chemistry Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Metabolic Signaling to the Central Nervous System: Routes Across the Blood Brain Barrier
Current Pharmaceutical Design Meet Our Editorial Board Member
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
Current Pharmacogenomics and Personalized Medicine PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications
Current Medicinal Chemistry Microvascular Theory of Exercise-Induced Bronchoconstriction in Asthma: Potential Implication of Vascular Endothelial Growth Factor
Inflammation & Allergy - Drug Targets (Discontinued)